Smither Sophie J, Garcia-Dorival Isabel, Eastaugh Lin, Findlay James S, O'Brien Lyn M, Carruthers Jonathan, Williamson E Diane, Molina-París Carmen, Hiscox Julian A, Laws Thomas R
CBR Division, Dstl Porton Down, Salisbury, United Kingdom.
Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Front Cell Infect Microbiol. 2020 Apr 21;10:159. doi: 10.3389/fcimb.2020.00159. eCollection 2020.
As the ongoing outbreak in the Democratic Republic of Congo illustrates, Ebola virus disease continues to pose a significant risk to humankind and this necessitates the continued development of therapeutic options. One option that warrants evaluation is that of defective genomes; these can potentially parasitize resources from the wild-type virus and may even be packaged for repeated co-infection cycles. Deletion and copy-back defective genomes have been identified and reported in the literature. As a crude, mixed preparation these were found to have limiting effects on cytopathology. Here we have used synthetic virology to clone and manufacture two deletion defective genomes. These genomes were tested with Ebola virus using cell culture and shown to inhibit viral replication; however, and against expectations, the defective genomes were not released in biologically significant numbers. We propose that EBOV might have yet unknown mechanisms to prevent parasitisation by defective interfering particles beyond the known mechanism that prevents sequential infection of the same cell. Understanding this mechanism would be necessary in any development of a defective interfering particle-based therapy.
正如刚果民主共和国持续爆发的疫情所表明的那样,埃博拉病毒病继续对人类构成重大风险,这就需要继续开发治疗方案。一个值得评估的选择是缺陷基因组;这些基因组可能会寄生野生型病毒的资源,甚至可能被包装用于重复的共同感染循环。文献中已经鉴定并报道了缺失和回文缺陷基因组。作为一种粗糙的混合制剂,发现它们对细胞病理学有局限性影响。在这里,我们使用合成病毒学方法克隆并制造了两个缺失缺陷基因组。这些基因组在细胞培养中与埃博拉病毒一起进行了测试,结果显示它们能够抑制病毒复制;然而,与预期相反,缺陷基因组并没有以具有生物学意义的数量释放出来。我们提出,埃博拉病毒可能还有未知的机制来防止被缺陷干扰颗粒寄生,这超出了已知的防止同一细胞连续感染的机制。在任何基于缺陷干扰颗粒的治疗开发中,了解这一机制都是必要的。